Analyst Ryan Langston from TD Cowen reiterated a Buy rating on Molina Healthcare and decreased the price target to $283.00 from $369.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Langston has given his Buy rating due to a combination of factors, despite the challenges Molina Healthcare is currently facing. The company has experienced significant cost pressures across its service lines, which has led to a downward revision of its FY25 earnings guidance. This has understandably caused concern among investors, as evidenced by a notable decline in the stock price following the announcement.
However, Langston’s decision to maintain a Buy rating suggests confidence in Molina Healthcare’s ability to navigate these pressures and improve its financial performance in the long term. The revised price target, based on updated earnings estimates, reflects a belief in the company’s potential for recovery and growth. Langston likely sees value in the stock at its current level, considering the anticipated adjustments and the company’s strategic initiatives to manage costs effectively.
In another report released on July 19, TR | OpenAI – 4o also upgraded the stock to a Buy with a $202.00 price target.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MOH in relation to earlier this year.